Tn-Glycoconjugates engage MGL2 to potentiate TLR9-mediated dendritic cell maturation and Th1-skewed immune responses
Innate Immunity · 2026
DOI: 10.1177/17534259261449674 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innate Immunity, 2026. Verfasst von Carolina Chiale und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Inmunomodulación y Vacunas, Unidad Académica de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay. Hauptthemen laut MEDLINE: Dendritic Cells, Toll-Like Receptor 9, Th1 Cells, Lectins, C-Type. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Comisión Sectorial de Investigación Científica.
Abstract (Originalsprache)
Dendritic cells (DCs) orchestrate antitumor immunity by integrating signals from the tumor microenvironment to prime effective T cell responses. Many tumors display altered glycosylation patterns, including tumor-associated carbohydrate antigens (TACAs) such as the Tn antigen (GalNAcα1- O -Ser/Thr); yet how these structures influence DC function is not well defined. Here, we investigated how Tn-bearing glycoconjugates modulate DC activation and shape adaptive immunity. Bone marrow-derived DCs (BMDCs) efficiently internalized fluorescently labeled Tn-glycoconjugates, whereas uptake of non-glycosylated counterparts was negligible. Although Tn-glycoconjugates alone did not induce DC maturation, co-stimulation with the Toll-like receptor 9 (TLR9) agonist CpG markedly increased CD86 expression and the secretion of IL-12/23p40 and IL-6, with the multivalent construct MAG:Tn3-PV eliciting the strongest response. These conditioned BMDCs promoted strong IFN-γ production by allogeneic splenocytes, consistent with a Th1-polarizing phenotype. Mechanistically, both uptake and CpG-enhanced activation required the C-type lectin receptor MGL2, as blockade of MGL or competition with GalNAc abrogated glycoconjugate uptake and CpG-enhanced cytokine induction. Pharmacological inhibition revealed that MGL2 signaling synergizes with TLR9 through the Syk–Raf-1–NF-κB axis. In vivo , mice immunized with DCs conditioned with Tn-glycoconjugate- plus CpG displayed enhanced splenocyte proliferation, increased IFN-γ secretion, and elevated cytotoxic activity without IL-10 induction, confirming a Th1-skewed response. Collectively, these findings identify MGL2 as a critical mediator of Tn-glycoconjugate sensing and unveil a synergistic C-type lectin receptor (CLR)–TLR9 cross-talk that amplifies DC maturation and cytotoxic immunity. This study provides mechanistic insight into how specific glycan–lectin interactions fine-tune innate receptor signaling, highlighting the potential of Tn-based glycoconjugates as immunomodulatory tools for vaccine design and cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Inmunomodulación y Vacunas, Unidad Académica de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
- Unité de Chimie des Biomolécules, Institut Pasteur, Université Paris Cité, CNRS UMR3523, Paris, France.
ORCID-Profile: Teresa Freire
Förderung
- Comisión Sectorial de Investigación Científica
Zitieren
APA
Chiale, C., Bay, S., Ganneau, C., & Freire, T. (2026). Tn-Glycoconjugates engage MGL2 to potentiate TLR9-mediated dendritic cell maturation and Th1-skewed immune responses. Innate Immunity. https://doi.org/10.1177/17534259261449674
Vancouver
Chiale C, Bay S, Ganneau C, Freire T. Tn-Glycoconjugates engage MGL2 to potentiate TLR9-mediated dendritic cell maturation and Th1-skewed immune responses. Innate Immunity. 2026. doi:10.1177/17534259261449674
BibTeX
@article{Chiale2026,
author = {Chiale, Carolina and Bay, Sylvie and Ganneau, Christelle and Freire, Teresa},
title = {Tn-Glycoconjugates engage MGL2 to potentiate TLR9-mediated dendritic cell maturation and Th1-skewed immune responses},
journal = {Innate Immunity},
year = {2026},
doi = {10.1177/17534259261449674}
}
EUVIMED